MEM 68626
MEM 68626, the lead development candidate in our 5-HT6 antagonist program, is a novel, potent and selective antagonist of the 5-HT6 receptor. The compound has demonstrated efficacy in multiple preclinical models of cognition and obesity and has a favorable safety and toxicology profile in in vivo studies. In addition, MEM 68626 has superior pharmaceutical-like properties and the compound's pharmacokinetic profile suggests the potential for once-daily, oral dosing. We plan to advance the compound into Phase 1 clinical trials.
In July 2008, the company presented data from its MEM 68626 program at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD).
To view the poster presentation, click here.